Accueil   Agenda - News   Toutes les news MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic

 

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 

 

- Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation

- MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors

 

Lyon, France, August 28, 2020 – MaaT Pharma announced today that clinical data from 11 patients treated with the company’s lead microbiome restoration biotherapeutic, MaaT013, will be presented in an e-poster at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held virtually from August 29 – September 1, 2020. MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a consistent richness of microbial species derived from pooled healthy donors to treat patients with intestinal acute Graft-versus-Host-Disease (aGvHD) following allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). MaaT Pharma provided MaaT013 to hospitals as part of its compassionate use program for patients who had previously received and failed up to five previous systemic treatments for GvHD.  MaaT Pharma will announce the results through a press release on Monday, August 31, 2020.

 

Read the press release